"Menorrhagia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Excessive uterine bleeding during MENSTRUATION.
| Descriptor ID |
D008595
|
| MeSH Number(s) |
C13.351.500.852.691.449 C23.550.568.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Menorrhagia".
Below are MeSH descriptors whose meaning is more specific than "Menorrhagia".
This graph shows the total number of publications written about "Menorrhagia" by people in this website by year, and whether "Menorrhagia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 3 | 0 | 3 |
| 2021 | 2 | 1 | 3 |
| 2022 | 5 | 0 | 5 |
| 2023 | 6 | 0 | 6 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Menorrhagia" by people in Profiles.
-
A systematic approach to the management of menses prophylaxis and suppression in pre-menopausal hematologic cancer patients. J Oncol Pharm Pract. 2024 Oct; 30(7):1259-1267.
-
Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary. J Comp Eff Res. 2024 08; 13(8):e230194.
-
Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study. Am J Obstet Gynecol. 2024 02; 230(2):237.e1-237.e11.
-
LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2023 12; 229(6):662.e1-662.e25.
-
A plain language summary of the long-term relugolix combination therapy study for uterine fibroids. J Comp Eff Res. 2023 08; 12(8):e230069.
-
Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial. F S Sci. 2023 Nov; 4(4):317-326.
-
A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies. Pain Manag. 2023 Apr; 13(4):205-211.
-
Standardising outcome reporting for clinical trials of interventions for heavy menstrual bleeding: Development of a core outcome set. BJOG. 2023 10; 130(11):1337-1345.
-
Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials. Am J Obstet Gynecol. 2023 03; 228(3):320.e1-320.e11.
-
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas. Obstet Gynecol. 2022 12 01; 140(6):920-930.